Visiopharm

Visiopharm is a leading private provider of AI-powered digital pathology software, headquartered in Hoersholm, Denmark. The company's core technology platform enables the development and deployment of deep learning applications (APPs) for quantitative tissue analysis across a wide range of diseases and research areas, including oncology, neuroscience, and fibrosis. With over 130 modular analysis units and nine IVDR-certified CE-IVD APPs, Visiopharm addresses critical needs in spatial biology, immunohistochemistry standardization, and diagnostic reproducibility. Its business model is focused on software licensing and solutions for the research and diagnostic markets, positioning it as a key enabler of precision medicine.

AI-driven digital pathology software platform featuring deep learning application (APP) development (Discovery), a library of pre-trained APPs (APP Center), multiplex image analysis for spatial biology (Phenoplex™), IHC quality control (Qualitopix), and IVDR-certified CE-IVD APPs for clinical diagnostics.

Visiopharm competes in a crowded and fast-evolving market. Key competitors include pure-play AI pathology firms like PathAI and Paige, as well as digital pathology hardware/software giants like Roche (Ventana) and Philips. Its differentiation lies in its long history, user-friendly platform for in-house APP development, and a growing portfolio of IVDR-certified clinical applications.